Safinamide (as add-on therapy) + Safinamide (as add-on therapy) + Safinamide (as add-on therapy)
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Idiopathic Parkinson's Disease
Conditions
Idiopathic Parkinson's Disease
Trial Timeline
Nov 1, 2007 → Mar 1, 2012
NCT ID
NCT00605683About Safinamide (as add-on therapy) + Safinamide (as add-on therapy) + Safinamide (as add-on therapy)
Safinamide (as add-on therapy) + Safinamide (as add-on therapy) + Safinamide (as add-on therapy) is a phase 3 stage product being developed by Newron Pharmaceuticals for Idiopathic Parkinson's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00605683. Target conditions include Idiopathic Parkinson's Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00605683 | Phase 3 | Completed |
Competing Products
20 competing products in Idiopathic Parkinson's Disease